• 1
    Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011—a core group report. J Hepatol 2011; 55: 1121-1131.
  • 2
    Wursthorn K, Jaroszewicz J, Zacher BJ, Darnedde M, Raupach R, Mederacke I, quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol 2011; 50: 292-296.
  • 3
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
  • 4
    Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-561.
  • 5
    Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52: 1232-1241.
  • 6
    Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-490.
  • 7
    Chan HL, Wong GL, Tse CH, Chan HY, Wong VW. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis 2011; 204: 408-414.
  • 8
    Chan HL. Identifying hepatitis B carriers at low risk for hepatocellular carcinoma. Gastroenterology 2012; 142: 1057-1060.
  • 9
    Piratvisuth T, Chan HL, Marcellin P, Wat C. Improved predictive values for sustained immune control in peginterferon alfa-2a (40KD) (Pegasys)-treated HBeAg-positive patients using combined HBsAg and HBV DNA levels at week 24. J Hepatol 2012; 56: S213-S214.
  • 10
    Gane EJ, Jia JD, Han KH. NEPTUNE study: on-treatment HBsAg level analysis confirms prediction of response observed in phase 3 study of peginterferon alfa-2a in HBeAg-positive patients. J Hepatol 2011; 54: S69.
  • 11
    Lau GK, Marcellin P, Brunetto MR. On treatment monitoring of HBsAg levels to predict response to peginterferon alfa-2a in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2009; 50: S333.
  • 12
    Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-1257.
  • 13
    Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-1150.
  • 14
    Takkenberg B, Zaaijer HL, De Niet A. Baseline HBsAg level and ontreatment HBsAg and HBV DNA decline predict sustained virological response in HBeAg-negative chronic hepatitis B patients treated with peginterferon alfa-2a (Pegasys) and Adefovir (Hepsera); an interim analysis. Hepatology 2009; 50: A491.
  • 15
    Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012; 56: 1006-1011.
  • 16
    Wong GL, Chan HL. Predictors of treatment response in chronic hepatitis B. Drugs 2009; 69: 2167-2177.
  • 17
    Lampertico P, Vigano M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, et al. Randomised study comparing 48 and 96 weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 2013; 62: 290-298.
  • 18
    Chan HL. Chronic Peginterferon therapy for chronic hepatitis B: one size fits all? Gut 2013; 62: 185-187.